MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis

Last updated: November 19, 2021
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Connective Tissue Diseases

Collagen Vascular Diseases

Scleroderma

Treatment

N/A

Clinical Study ID

NCT04244916
APHP190933
  • Ages > 18
  • All Genders

Study Summary

To define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse cutaneous or interstitial lung damage of systemic sclerosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Systemic sclerosis meeting the ACR / EULAR criteria of 2013
  • Equal or more than 18 years old, able to freely consent to study
  • In patients treated for skin damage:
  • Diffuse skin sclerosis (rising above the elbows and / or knees)
  • First clinical sign of systemic sclerosis outside of Raynaud's phenomenon goingback less than three years
  • Failure to take other concomitant immunosuppressive treatments or in the last 3months except corticosteroids.
  • In patients treated for lung damage:
  • Interstitial lung damage identified on chest CT, chest x-ray
  • Any duration of progression of systemic scleroderma
  • Prescription of MMF in first line or in relay of a treatment withCyclophosphamide.
  • Absence of biotherapy in the last 6 months.

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 50
Study Start date:
May 25, 2020
Estimated Completion Date:
September 25, 2023

Study Description

In the treatment of autoimmune diseases, MMF is almost always prescribed at a fixed dose, regardless of AUC, or based on the target of AUC determined for organ transplantation. One study looked at determining an "effective" AUC threshold in systemic lupus erythematosus, which appears to be 35mg / h / l. This was also done for ANCA vasculitis.

We therefore conducted this study to determine a correlation between AUC MPA and the effectiveness of MMF in systemic sclerosis.

Prospective, observational, open study.

Main objective: define a target value of AUC MPA to improve the modified Rodnan score and / or respiratory impairment (DLCO or FVC) at one year in patients receiving MMF for the treatment of diffuse skin involvement or pulmonary function in systemic sclerosis.

The main endpoint will be evaluated on the evolution of the modified Rodnan score at 1 year after the initiation of MMF and / or the evolution of FVC and DLCO at 1 year after the initiation of MMF.

Connect with a study center

  • Cochin hospital, AP-HP

    Paris, 75014
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.